Tensions show no sign of easing ahead of President Xi Jinping’s upcoming meeting with Obama
Time has run out for Procter & Gamble's CEO as the company turns to a famed management star
Surprise, surprise: Target, Macy's, and 15 other retailers are suing Visa and MasterCard over card fees
The odd-job marketplace is getting traction with business customers
Net flow into debt hedge funds is the highest since 2007
Roel Vertegaal's PaperTab is like an iPad you can fold, spindle, or mutilate
Networks are staggering première dates to capture viewers and ad dollars
Jim Dean, the dean of UNC's Kenan-Flagler School, calls it quits for a more lofty title: provost
Rob Rhinehart is living on a substance he engineered to replace food, and he just raised more than $200,000 through crowdfunding to manufacture it
Founders: Jeff Stein, John Finn, and John Schmid
VC Investment over the last four quarters: $35.16 million
Founded in 2004, the 35-employee biopharmaceutical company is working to develop antibacterial drugs to treat infections caused by resistant bacteria. Besides the VC investment, Stein says Trius has raised $32 million in government grants and contracts. As far as his perspective on the impact of the recession on his company, which expects less than $1 million in revenues in 2008, Stein says it will make the fundraising environment more challenging and may impact the partner environment as well.
Key to startup success: "Recruit top-tier executives. Focus on advancing your most valuable asset and seek alternative financing for earlier-stage programs."